Bg pattern

INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Infutraze concentrated solution for infusion

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or nurse.
  • If your child experiences any side effects, talk to your doctor or nurse, even if you think they might be unrelated to this medicine. See section 4.

Contents of the Package Leaflet

  1. What is Infutraze and what is it used for
  2. What you need to know before you use Infutraze
  3. How to use Infutraze
  4. Possible side effects
  5. Storage of Infutraze
  6. Contents of the pack and other information

1. What is Infutraze and what is it used for

Infutraze is a mixture of trace elements administered into the blood by drip (intravenous perfusion). Infutraze contains five trace elements (zinc, copper, manganese, selenium, and iodine) in very small amounts that are normally absorbed from food. These trace elements are necessary for the normal functioning of the body.

Infutraze is used to cover the basic needs of trace elements in premature and full-term newborns, infants, children, and adolescents who cannot eat or absorb enough food through tube feeding and therefore need intravenous nutrition (so-called parenteral nutrition). Infutraze is added to parenteral nutrition containing all the nutrients the body needs.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Infutraze

Do not use Infutraze if your child:

  • is allergic to the active substances or to any of the other ingredients of this medicine (listed in section 6).
  • has Wilson's disease.

Warnings and precautions

Talk to your doctor before starting Infutraze if your child has:

  • kidney problems
  • liver problems
  • reduced bile excretion
  • thyroid problems (hyperthyroidism)

During treatment, your doctor will periodically check the levels of trace elements in the blood. Your doctor will adjust the dose of Infutraze accordingly.

Children and adolescents

Infutraze is indicated for premature and full-term newborns, infants, children, and adolescents.

Other medicines and Infutraze

Tell your doctor if your child is taking, has recently taken, or might take any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, talk to your doctor before using Infutraze.

Infutraze contains sodium and potassium

This medicine contains less than 23 mg of sodium (1 mmol) per 10 ml ampoule; this is essentially 'sodium-free'.

This medicine contains less than 39 mg (1 mmol) of potassium per 10 ml ampoule, which is considered essentially 'potassium-free'.

3. How to use Infutraze

Infutraze will be administered to your child in the form of intravenous perfusion (into the blood through a drip) by a healthcare professional. Infutraze will always be diluted in another parenteral nutrition solution.

Your doctor will decide on the individual dose for your child based on body weight and activity.

A daily infusion of iron is recommended when parenteral nutrition is administered for more than 3 weeks, and a perfusion of molybdenum should also be administered when parenteral nutrition is administered for more than 4 weeks.

If too much Infutraze is administered

It is unlikely that your child will receive too much Infutraze, as the perfusion will be controlled by a healthcare professional. If you think your child has received too much Infutraze, talk to your doctor.

If you have any other questions about the use of this medicine, ask your doctor or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

No side effects have been reported.

Reporting of side effects

If your child experiences any side effects, talk to your doctor, pharmacist, or nurse. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Infutraze

Keep this medicine out of the sight and reach of children.

Do not store above 25°C. Do not freeze.

Do not use this medicine if you notice visible signs of deterioration.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the ampoule after EXP. The expiry date is the last day of the month shown.

Shelf-life after mixing

Stability after mixing has been demonstrated for a maximum of 7 days at 2-8°C followed by 48 hours at 20°C-25°C, including the duration of administration. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage time and conditions before use are the responsibility of the user and normally should not exceed 24 hours at 2-8°C.

6. Contents of the pack and other information

Composition of Infutraze

The active substances are:

Infutraze

1 ml

1 ampoule (10 ml)

Zinc chloride

1042 micrograms

10420 micrograms

Copper(II) chloride dihydrate

107.4 micrograms

1074 micrograms

Manganese(II) chloride tetrahydrate

3.600 micrograms

36.00 micrograms

Sodium selenite

15.33 micrograms

153.3 micrograms

Potassium iodide

2.567 micrograms

25.67 micrograms

The active substances in 1 ml of Infutraze correspond to:

Zinc (Zn)

7.64 micromoles

500 micrograms

Copper (Cu)

0.630 micromoles

40.0 micrograms

Manganese (Mn)

0.0182 micromoles

1.00 microgram

Selenium (Se)

0.0887 micromoles

7.00 micrograms

Iodine (I)

0.0155 micromoles

1.96 micrograms

The other ingredients are

Hydrochloric acid (for pH adjustment)

Water for injections

Appearance of Infutraze and pack contents

Infutraze, concentrated solution for infusion, is a clear and almost colorless solution. It is presented in 10 ml transparent ampoules made of polypropylene.

Package sizes:

20 x 10 ml in a cardboard box

Marketing authorisation holder and manufacturer

Manufacturer:

HP Halden Pharma AS

Svinesundsveien 80

1788 Halden

Norway

Marketing authorisation holder:

Fresenius Kabi España, S.A.U.

Torre Mapfre-Vila Olímpica

C/Marina 16-18

08005 Barcelona

Spain

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Austria

Kidtrayze Konzentrat zur Herstellung einer Infusionslösung

Belgium

Kidtrayze concentraat voor oplossing voor infusie

Kidtrayze solution à diluer pour perfusion

Kidtrayze Konzentrat zur Herstellung einer Infusionslösung

Bulgaria

????????? ????? ?????????? ?? ?????????? ???????

Peditrace Novum concentrate for solution for infusion

Croatia

Peditrace Novum koncentrat za otopinu za infuziju

Cyprus

Kidtrayze πυκν? δι?λυμα για παρασκευ? διαλ?ματος προς ?γχυση

Czech Republic

Peditrace Novum

Denmark

Peditrace Novum

Estonia

Infutraze

Finland

Kidtrayze

France

Peditrace solution à diluer pour perfusion

Germany

Kidtrayze Konzentrat zur Herstellung einer Infusionslösung

Greece

Kidtrayze πυκν? δι?λυμα για παρασκευ? διαλ?ματος προς ?γχυση

Hungary

Infutraze koncentrátum oldatos infúzióhoz

Iceland

Peditrace Novum

Italy

Kidtrayze

Ireland

Infutraze concentrate for solution for infusion

Latvia

Infutraze koncentrats infuziju šķīduma pagatavošanai

Lithuania

Infutraze koncentratas infuziniam tirpalui

Luxembourg

Kidtrayze

Malta

Kidtrayze

Netherlands

Kidtrayze concentraat voor oplossing voor infusie

Norway

Kidtrayze

Poland

Peditrace Novum

Portugal

Kidtrayze

Romania

Kidtrayze concentrat pentru solutie perfuzabila

Slovakia

Peditrace

Slovenia

KIDTRAYZE koncentrat za raztopino za infundiranje

Spain

Infutraze

Sweden

Peditrace Novum

United Kingdom

(Northern Ireland)

Infutraze concentrate for solution for infusion

Date of last revision of this leaflet:October 2023

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)

<----------------------------------------------------------------------------------------------------------------->

This information is intended only for healthcare professionals:

Special warnings and precautions for use

Infutraze should be used with caution in patients with renal dysfunction, in whom the excretion of selenium, zinc, and iodine may be significantly decreased. There is a higher risk of accumulation of trace elements in these patients.

Infutraze should be used with caution in patients with hepatic dysfunction (especially cholestasis) in whom the excretion of copper and manganese may be decreased.

In patients with altered bile excretion, the elimination of manganese, copper, and zinc may be reduced. Clinical signs of accumulation of trace elements may require a reduction in the dose or discontinuation of Infutraze in these patients.

Dose adjustment may be necessary in patients with renal dysfunction and hepatic dysfunction or mild cholestasis.

Infutraze should be used with caution in patients with hyperthyroidism. In these patients, iodine may increase the symptoms of hyperthyroidism (e.g., goiter).

No dose adjustment of Infutraze is necessary in case of additional iodine intake through iodized antiseptics.

Long-term parenteral nutrition

In patients receiving long-term parenteral nutrition, accumulation of trace elements may occur, especially manganese. If treatment is prolonged for more than 4 weeks, manganese levels should be monitored. The appearance of neurological signs (e.g., anxiety, rapid eye movements) may indicate possible manganese overload, which may also be derived from certain medical conditions and parenteral nutrition. Manganese accumulation may require a reduction in the dose or discontinuation of Infutraze.

In patients receiving long-term parenteral nutrition, a deficiency of trace elements may occur, especially copper, zinc, and selenium. In case of deficiency, these individual trace elements should be supplied separately.

Posology

Preterm neonates:

A maximum recommended daily dose of 1.0 ml of Infutraze per kg of body weight covers the basic needs of the included trace elements.

Full-term neonates, infants, and children weighing less than 20 kg:

A maximum recommended daily dose of 0.5 ml of Infutraze per kg of body weight covers the basic needs of the included trace elements.

Children weighing more than 20 kg and adolescents:

A maximum recommended daily dose of 10 ml of Infutraze covers the basic needs of the included trace elements.

The following amounts of trace elements are contained in 0.5 ml, 1.0 ml, and 10 ml of Infutraze:

0.5 ml

1.0 ml

10 ml

Zn

250 micrograms

500 micrograms

5000 micrograms

Cu

20.0 micrograms

40.0 micrograms

400 micrograms

Mn

0.50 micrograms

1.00 micrograms

10.0 micrograms

Se

3.50 micrograms

7.00 micrograms

70.0 micrograms

I

0.98 micrograms

1.96 micrograms

19.6 micrograms

In addition to the trace elements contained in Infutraze, daily infusions of iron are recommended if patients receive parenteral nutrition for more than 3 weeks. A perfusion of molybdenum should also be administered if patients receive parenteral nutrition for more than 4 weeks.

Method of administration

Infutraze must not be administered undiluted. Infutraze will be administered in intravenous perfusion, diluted in a parenteral nutrition solution/emulsion. The speed and duration of the perfusion are determined by the speed and duration of the perfusion of the parenteral nutrition solution.

Infutraze can only be mixed with other nutritional products whose compatibility has been documented, see the Compatibility section below.

Special precautions for disposal and other handling

Before use, check visually that the concentrated solution for infusion is transparent and free of particles.

Compatibility

Dilute before use.

Infutraze is used as an additive for parenteral nutrition mixtures when compatibility data are available.

Compatibility data are available for the following products: Aminoven Infant, Vaminolact, Vamin 14, Vamin 18, Smoflipid, Intralipid, Vitalipid adult, Vitalipid infant, Soluvit N, Addiphos, and Glycophos in defined quantities, combined with generic glucose and electrolytes in defined quantities. Infutraze can also be added to SmofKabiven and SmofKabiven EF with or without Vitalipid N Infant/Adult and Soluvit N and electrolytes. The generated data support the additions according to the following summary table:

Infutraze

Mixture

0-10 ml/l

Aqueous PN mixtures with the components listed above.

0-10 ml/l

PN mixtures containing lipids with the components listed above

0-10 ml

SmofKabiven and SmofKabiven EF (activated bag of 986 ml, 1477 ml, 1970 ml, or 2463 ml) with electrolytes and vitamins as indicated above

0-5 ml

SmofKabiven and SmofKabiven EF (activated bag of 493 ml) with electrolytes and vitamins as indicated above

Infutraze should never be added directly to a lipid emulsion due to its destabilizing effects. It is recommended to mix the macronutrients (amino acid solution and glucose with or without lipid emulsion) before adding the micronutrients. Additions should be made aseptically.

The disposal of unused medicine and all materials that have been in contact with it should be done in accordance with local regulations.

Shelf-life after mixing

Stability after mixing (see Compatibility section) has been demonstrated for a maximum of 7 days at 2-8°C followed by 48 hours at 20°C-25°C, including the duration of administration. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage time and conditions before use are the responsibility of the user and normally should not exceed 24 hours at 2-8°C.

Online doctors for INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION

Discuss questions about INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (760)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50

Frequently Asked Questions

Is a prescription required for INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION?
INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION?
The active ingredient in INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION is electrolytes in combination with other drugs. This information helps identify medicines with the same composition but different brand names.
Who manufactures INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION?
INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION is manufactured by Fresenius Kabi España, S.A.U.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to INFUTRAZE CONCENTRATE FOR PERFUSION SOLUTION?
Other medicines with the same active substance (electrolytes in combination with other drugs) include SUPLIVEN CONCENTRADO FOR PERFUSION SOLUTION, POTASSIUM ACETATE B.BRAUN 1 mEq/ml CONCENTRATE FOR INFUSION SOLUTION, SODIUM BICARBONATE 1/6 M MEIN SOLUTION FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media